EMA Lists Five Drugs as Preferred COVID-19 Therapeutics
The European Medicines Agency (EMA) has issued a list of five preferred therapeutics for COVID-19 patients, including four monoclonal antibodies and Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib).
The agency recommended antibodies from GlaxoSmithKline, Celltrion, Eli Lilly and Regeneron for use in early-stage patients at risk of progressing to severe COVID-19 and Olumiant for treatment of hospitalized COVID-19 patients on oxygen.
The EMA, which plans to expand its preferred list to include 10 treatments, released the list for use by regulatory authorities in EU member states. The only COVID-19 treatment currently approved in the EU is Gilead Sciences’ Veklury (remdesivir).